4-(cyclohex-1-en-1-yl)butanal | 50639-01-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(cyclohex-1-en-1-yl)butanal
• 英文别名: cyclohex-1-ene-1-butanal；4-(1-Cyclohexenyl)-butyraldehyde；4-(cyclohexen-1-yl)butanal
• CAS: 50639-01-5
• 化学式: C₁₀H₁₆O
• 分子量: 152.236
• InChiKey: JBBYTHPLCPTXLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(cyclohex-1-en-1-yl)butanal 在 盐酸羟胺 、 sodium acetate 作用下， 以 水 、 乙腈 为溶剂， 反应 3.5h， 生成 1-Hydroxy-7-phenylselanyl-1-azonia-spiro[5.5]undec-1-ene; bromide
  参考文献：
  名称：

  Spiro- and bridged-ring forming electrophile induced → oxime → nitrone cycloaddition cascades. Multiplication of chirality

  摘要：

  Electrophile induced 6-exo-trig spirocyclisation of oximes onto 5-, 6- or 7-membered cycloalkenes occurs stereo- and regio- specifically in good yield. Bridged - ring forming cyclisations creating bicycle-[3.3.1]- and bicyclo-[3.2.1]-ring systems also occur in good yield. Chiral bridged-ring systems have been synthesised, via the latter processes, that involve multiplication of chiral centres from one to six and seven in one pot reactions. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01255-0
• 作为产物：
  描述：

  亚甲基环己烷 在 三氯化铝 、 二异丁基氢化铝 作用下， 以 甲苯 、 苯 为溶剂， 反应 49.0h， 生成 4-(cyclohex-1-en-1-yl)butanal
  参考文献：
  名称：

  Spiro- and bridged-ring forming electrophile induced → oxime → nitrone cycloaddition cascades. Multiplication of chirality

  摘要：

  Electrophile induced 6-exo-trig spirocyclisation of oximes onto 5-, 6- or 7-membered cycloalkenes occurs stereo- and regio- specifically in good yield. Bridged - ring forming cyclisations creating bicycle-[3.3.1]- and bicyclo-[3.2.1]-ring systems also occur in good yield. Chiral bridged-ring systems have been synthesised, via the latter processes, that involve multiplication of chiral centres from one to six and seven in one pot reactions. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01255-0

文献信息

• [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009136663A1

  公开（公告）日：2009-11-12

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• [EN] HETEROARYLS AND THEIR USE AS PI3K INHIBITORS<br/>[FR] HÉTÉROARYLES ET APPLICATIONS ASSOCIÉES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010090716A1

  公开（公告）日：2010-08-12

  This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了式（IA）或（IB）的化合物：其中R1、R2、G1和HY如规范中所述。这些化合物是PI3K和/或mTor的抑制剂，因此可用于治疗增殖性、炎症性或心血管疾病。
• γ,δ- andδ,ɛ-Unsaturated Aldehydes fromγ- andδ-Lactones in One Step. Preliminary Communication
  作者：Wolfgang Giersch、Ferdinand Naef

  DOI：10.1002/hlca.200490153

  日期：2004.7

  A one-step transformation of γ- and δ-(spiro)lactones into γ,δ- and δ,ε-unsaturated aldehydes with an excess of formic acid in the vapor phase over a supported manganese catalyst is described for the first time. The scope and limitations of this new reaction are shown with different lactones as substrate, and a mechanistic rationale is proposed.

  的一步法转化γ -和δ - （螺）内酯成γ，δ -和δ，ε不饱和醛与在气相中在支撑锰催化剂的过量的甲酸的首次被描述。以不同的内酯为底物，显示了该新反应的范围和局限性，并提出了机理学依据。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Okaniwa Masanori

  公开号：US20110237620A1

  公开（公告）日：2011-09-29

  A compound represented by formula (I) or a salt thereof, which has a potent Raf inhibitory activity. In formula (I), R 1 represents an optionally substituted C 1-6 alkyl, etc.; X represents —O— or —NR 2 — (wherein R 2 represents a hydrogen atom or a C 1-6 alkyl); Y represents a group represented by formula 2 ( 2 ii or 2 ii) (wherein ring A represents an optionally substituted benzene ring; Z represents a group represented by (1) —NR 3 CO—W 1 —, (2) —NR 3 CO—W 1 —O—, (3) —NR 3 CO—W 1 —O—W 2 —, (4) —NR 3 CO—W 1 —S—, (5) —NR 3 CO—W 1 —NR 4 —, (6) —NR 3 COO—, (7) —NR 3 COO—W 1 —, (8) —NR 3 CO—CO—, or (9) —NR 3 CONR 4 — (wherein R 3 and R 4 each represents a hydrogen atom, etc., and W 1 and W 2 each represents an optionally substituted C 1-6 alkylene, etc.); and R 5 represents an optionally substituted five- or six-membered ring group.

  化合物的化学式（I）或其盐，具有强大的Raf抑制活性。在化学式（I）中，R1代表一个可选择取代的C1-6烷基等；X代表—O—或—NR2—（其中R2代表氢原子或C1-6烷基）；Y代表由化学式2（2ii或2ii）表示的基团（其中环A代表可选择取代的苯环；Z代表由（1）—NR3CO—W1—，（2）—NR3CO—W1—O—，（3）—NR3CO—W1—O—W2—，（4）—NR3CO—W1—S—，（5）—NR3CO—W1—NR4—，（6）—NR3COO—，（7）—NR3COO—W1—，（8）—NR3CO—CO—，或（9）—NR3CONR4—（其中R3和R4各代表氢原子等，W1和W2各代表可选择取代的C1-6烷基等））；R5代表一个可选择取代的五元或六元环基团。